https://www.selleckchem.com/pr....oducts/aminooxyaceti
MRD negativity was achieved in three pre-transplant MRD positive patients by the sixth month of HSCT. They sustained hematological and molecular remission for 19, 9 and 7 months, respectively. The fourth patient died due to transplant-related complications. According to our experience, when molecularly-defined AML patients undergo HSCT, regular MRD monitoring helps predict impending relapse and direct future treatment strategies. According to our experience, when molecularly-defined AML patients undergo HSC
Like
Comment
Share
